Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Rischin, D; Harrington, KJ; Greil, R; Soulieres, D; Tahara, M; de Castro, G; Psyrri, A; Baste, N; Neupane, PC; Bratland, A; Fuereder, T; Hughes, BGM; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Zhang, YY; Jin, F; Gumuscu, B; Burtness, B

View this publication in the PUBMED database